Encouraging Early Data From Next-Gen Study Puts Bristol Myers' CAR T Therapy In The Spotlight For Autoimmune Diseases
Bristol Myers reports promising preliminary results for its next-gen CAR T therapy CC-97540, showing safety and early efficacy in a Phase 1 study for severe autoimmune diseases.
Is Bristol-Myers Squibb Company (BMY) the Best Immunotherapy Stock to Buy Now?
We recently compiled a list of the 10 Best Immunotherapy Stocks to Buy Now. In this article, we are going to take a look at ...
BioSpace1d
AbbVie’s Setback Gives BMS Commanding Lead in Schizophrenia Space
With the failure of AbbVie’s emraclidine in two mid-stage trials, Bristol Myers Squibb’s Cobenfy is 'sole muscarinic winner.' ...
Seeking Alpha2d
Bristol-Myers Squibb: Buy This Bargain Before It's Gone
Bristol-Myers Squibb's stock price has risen more than 25% over the past six months, reflecting significant progress in its ...
Prime Medicine Reports Q3 2024 Financial Progress
Prime Medicine, Inc. ( (PRME) ) has released its Q3 earnings. Here is a breakdown of the information Prime Medicine, Inc. presented to its ...
Business Insider6d
Prime Medicine, Inc. Receives Buy Rating from Arthur He CFA: Strategic Partnerships and Pipeline Focus Drive Promising Future Prospects
H.C. Wainwright analyst Arthur He CFA maintained a Buy rating on Prime Medicine, Inc. (PRME – Research ... by a $55M upfront payment from a strategic partnership with Bristol Myers Squibb. This ...
Prime Medicine Reports Third Quarter 2024 Financial Results and Provides Business Updates
Presented initial in vivo data for universal liver-targeted LNP and Wilson’s Disease program at ESGCT; initiated IND-enabling ...